Business
ClearPoint Neuro Announces the Appointment of Dr. Paul Larson as Chief Medical Officer
SOLANA BEACH, CALIFORNIA / ACCESS Newswire / September 25, 2025 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that ...
About this update from Clearpoint Neuro Inc.
[{"type":"text","content":"SOLANA BEACH, CALIFORNIA / ACCESS Newswire / September 25, 2025 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that Dr. Paul Larson will be joining the company as Chief Medical Officer starting in January 2026. Dr. Larson has a long history of working with ClearPoint Neuro as an advisor, especially supporting education and product development efforts related to cell and gene therapy delivery. Dr. Larson will continue his appointments at both the University of California San Francisco and at Banner Hospital, University of Arizona where he will continue to enroll patients in various ongoing cell and gene therapy clinical trials.","length":778,"tagName":"p"},{"type":"text","content":""We are thrilled to have Paul join our team in this very significant role and at the perfect time," commented Joe Burnett, President and CEO of ClearPoint Neuro. "Paul has been a part of the ClearPoint Neuro history from the very start, through his expert knowledge of neuro navigation and drug delivery, as well as his passion for mentoring and coaching in totally new treatment paradigms. In the field of neuro cell and gene therapy, Paul has played an essential role alongside some of the earliest investigators in this space having personally performed or overseen more than one hundred cell and gene therapy clinical procedures. Now that ClearPoint Neuro and our partners are preparing for the commercialization of these new-to-world therapies, Paul is a perfect fit to both educate and amplify access to these therapies using his substantial knowledge of best practices for neuro drug delivery worldwide."","length":931,"tagName":"p"},{"type":"text","content":""This is a very exciting time for the field of neurosurgery as multiple new cell and gene therapy treatments are quickly progressing under the FDA expedited review process," commented Paul Larson, M.D. "These new direct-delivery drug platforms are crucially important if we as a medical profession want to make progress in not only treating symptoms, but in potentially altering the course of the underlying disease for disorders like Huntington's Disease, Parkinsons' Disease, epilepsy, dementias, tumors, rare childhood gene...